Immucor Inc. (BLUD, Financial) filed Quarterly Report for the period ended 2010-11-30.
Immucor Inc. has a market cap of $1.35 billion; its shares were traded at around $19.31 with a P/E ratio of 16.7 and P/S ratio of 4.1. Immucor Inc. had an annual average earning growth of 48.3% over the past 10 years. GuruFocus rated Immucor Inc. the business predictability rank of 3.5-star.BLUD is in the portfolios of Richard Pzena of Pzena Investment Management LLC, Ron Baron of Baron Funds, Jim Simons of Renaissance Technologies LLC, Bruce Kovner of Caxton Associates, George Soros of Soros Fund Management LLC, Mario Gabelli of GAMCO Investors, Steven Cohen of SAC Capital Advisors.
During the three months ended November 30, 2010, revenue decreased by approximately $1.0 million or 1% compared with revenue in the prior year quarter. Revenue in the current year quarter was negatively impacted by approximately $1.0 million from fluctuations in foreign currency exchange rates. Additionally, there was an increase in revenue of approximately $0.9 million related to price contribution in the current year quarter that was offset by a decrease of approximately $0.9 million from volume contribution, which included incremental revenue from instrument placements. Volume contribution was negatively impacted in the current year quarter compared with the second quarter of fiscal 2010 due to lower sales volume of reagents because of weaker industry demand in the U.S. market as well as fewer ship cycles.
During the six months ended November 30, 2010, revenue decreased by approximately $0.5 million or less than 1% when compared with revenue in the prior year period. This decrease was primarily attributable to the negative impact from fluctuations in foreign currency exchange rates of approximately $2.4 million offset by the positive impact of approximately $1.9 million from price contribution during the current year period. Volume contribution was flat on a year-over-year basis for the first six months of fiscal 2011 with incremental revenue generated from instrument placements being offset by lower sales volume of reagents in the U.S. market due to weaker industry demand and fewer ship cycles.
Read the The complete Report
Immucor Inc. has a market cap of $1.35 billion; its shares were traded at around $19.31 with a P/E ratio of 16.7 and P/S ratio of 4.1. Immucor Inc. had an annual average earning growth of 48.3% over the past 10 years. GuruFocus rated Immucor Inc. the business predictability rank of 3.5-star.BLUD is in the portfolios of Richard Pzena of Pzena Investment Management LLC, Ron Baron of Baron Funds, Jim Simons of Renaissance Technologies LLC, Bruce Kovner of Caxton Associates, George Soros of Soros Fund Management LLC, Mario Gabelli of GAMCO Investors, Steven Cohen of SAC Capital Advisors.
Highlight of Business Operations:
Quality Process Improvement Project – During our third quarter of fiscal 2009, we formalized our efforts to improve the processes and procedures of our quality system through the establishment of the Quality Process Improvement Project. The Project expanded the role of consultants hired in April 2008. The Project s objective is to both remediate the deficiencies noted by FDA and to deliver on our commitment of maintaining a world-class quality system. During fiscal 2010 and fiscal 2009, we spent approximately $5.9 million and $2.4 million, respectively, on the Project. These costs were reflected in cost of sales and primarily represent the cost of external consultants who were assisting us with the Project. During our third fiscal quarter of 2010, we completed the first phase of the Project, which was designed to remediate the deficiencies from the January 2009 inspection as well as other high-risk compliance areas. The second phase of the Project continues with a focus on lower and medium risk compliance areas as well as the deficiencies noted in the FDA s June 2010 inspection. We will use primarily internal resources on the Project going forward.During the three months ended November 30, 2010, revenue decreased by approximately $1.0 million or 1% compared with revenue in the prior year quarter. Revenue in the current year quarter was negatively impacted by approximately $1.0 million from fluctuations in foreign currency exchange rates. Additionally, there was an increase in revenue of approximately $0.9 million related to price contribution in the current year quarter that was offset by a decrease of approximately $0.9 million from volume contribution, which included incremental revenue from instrument placements. Volume contribution was negatively impacted in the current year quarter compared with the second quarter of fiscal 2010 due to lower sales volume of reagents because of weaker industry demand in the U.S. market as well as fewer ship cycles.
During the six months ended November 30, 2010, revenue decreased by approximately $0.5 million or less than 1% when compared with revenue in the prior year period. This decrease was primarily attributable to the negative impact from fluctuations in foreign currency exchange rates of approximately $2.4 million offset by the positive impact of approximately $1.9 million from price contribution during the current year period. Volume contribution was flat on a year-over-year basis for the first six months of fiscal 2011 with incremental revenue generated from instrument placements being offset by lower sales volume of reagents in the U.S. market due to weaker industry demand and fewer ship cycles.
Read the The complete Report
